Amanda E. Coleman

Amanda E. Coleman

Auto-generated profile, based on publicly available information

Amanda E. Coleman

Department of Small Animal Medicine and Surgery, University of Georgia College of Veterinary Medicine, Athens, GA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2018 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
MAMark J. Acierno
Mark J. Acierno
SBScott Brown
Scott Brown
ACAmanda E. Coleman
Amanda E. Coleman
RJRosanne E. Jepson
Rosanne E. Jepson
MPMark G. G. Papich
Mark G. G. Papich
HSHarriet M. Syme
Harriet M. Syme
An update to the 2007 American College of Veterinary Internal Medicine (ACVIM) consensus statement on the identification, evaluation, and management of systemic hypertension in dogs and cats was presented at the 2017 ACVIM Forum in National Harbor, MD. The updated consensus statement is presented here. The consensus statement aims to provide guidance on appropriate diagnosis and treatment of hypertension in dogs and cats.

1 March 2019 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
ACAmanda E. Coleman
Amanda E. Coleman
SBScott A. Brown
Scott A. Brown
ATAnne M. Traas
Anne M. Traas
LBLawrence Bryson
Lawrence Bryson
TZTanja Zimmering
Tanja Zimmering
AZAlicia Zimmerman
Alicia Zimmerman
Background: Information regarding the efficacy of telmisartan for feline systemic arterial hypertension is limited. Objectives: To evaluate the safety and efficacy of PO administered telmisartan solution in hypertensive cats. Animals: Client-owned cats with indirect systolic arterial blood pressure (SBP) of 160-200 mm Hg, based on multiple measurements. Methods: This multicenter trial consisted a 28-day, prospective, randomized, double-blind, placebo-controlled, parallel group, efficacy phase and a 154-day extended-use telmisartan phase. Hypertensive cats were randomly assigned to receive 1.5 mg telmisartan/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h, or equivalent volume of placebo. Systolic blood pressure was measured on days 0, 14, and 28. Change in SBP compared to baseline was calculated for days 14 and 28. Telmisartan efficacy was defined as significant decrease in SBP at day 14 compared to placebo and a clinically relevant (>20 mm Hg) decrease in SBP at day 28. Results: Two-hundred twenty-one cats were included. On day 14, least squares mean (95% confidence interval) SBP decrease was significantly larger in telmisartan-treated (−23.3 mm Hg [−28.2 to −18.3]) versus placebo-treated (−7.5 mm Hg [−13.6 to −1.5]) cats (P = .0005). On day 28, telmisartan treatment resulted in a clinically relevant SBP decrease (−23.9 mm Hg [−27.8 to −20.0]), whereas placebo did not (−11.6 mm Hg [−17.4 to −5.9 mm Hg]). The decrease in SBP persisted over the 6-month trial in telmisartan-treated cats. Conclusions and Clinical Importance: Telmisartan significantly decreased SBP to a clinically relevant extent and was well tolerated in hypertensive cats.

1 September 2015 in American Journal of Veterinary Research
Verified
Journal Article
Open access
TJTiffany L. Jenkins
Tiffany L. Jenkins
ACAmanda E. Coleman
Amanda E. Coleman
CSChad Schmiedt
Chad Schmiedt
SBScott A. Brown
Scott A. Brown
OBJECTIVE To compare the attenuation of the angiotensin I–induced blood pressure response by once-daily oral administration of various doses of angiotensin receptor blockers (irbesartan, telmisartan, and losartan), benazepril hydrochloride, or lactose monohydrate (placebo) for 8 days in clinically normal cats. ANIMALS 6 healthy cats (approx 17 months old) with surgically implanted arterial telemetric blood pressure–measuring catheters. PROCEDURES Cats were administered orally the placebo or each of the drug treatments (benazepril [2.5 mg/cat], irbesartan [6 and 10 mg/kg], telmisartan [0.5, 1, and 3 mg/kg], and losartan [2.5 mg/kg]) once daily for 8 days in a crossover study. Approximately 90 minutes after capsule administration on day 8, each cat was anesthetized and arterial blood pressure measurements were recorded before and after IV administration of each of 4 boluses of angiotensin I (20, 100, 500, and 1,000 ng/kg). This protocol was repeated 24 hours after benazepril treatment and telmisartan (3 mg/kg) treatment. Differences in the angiotensin I–induced change in systolic arterial blood pressure (ΔSBP) among treatments were determined. RESULTS At 90 minutes after capsule administration, only losartan did not significantly reduce ΔSBP in response to the 3 higher angiotensin doses, compared with placebo. Among drug treatments, telmisartan (3 mg/kg dosage) attenuated ΔSBP to a significantly greater degree than benazepril and all other treatments. At 24 hours, telmisartan was more effective than benazepril (mean ± SEM ΔSBP, 15.7 ± 1.9 mm Hg vs 55.9 ± 12.42 mm Hg, respectively). CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that telmisartan administration may have advantages over benazepril administration for cats with renal or cardiovascular disease.

1 September 2016 in Veterinary Anaesthesia and Analgesia
Verified
Journal Article
Closed access
PDF file
ACAmanda E. Coleman
Amanda E. Coleman
MSMolly K. Shepard
Molly K. Shepard
CSChad W. Schmiedt
Chad W. Schmiedt
EHErik H. Hofmeister
Erik H. Hofmeister
SBScott A. Brown
Scott A. Brown

1 November 2014 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
ABA.C. Bugbee
A.C. Bugbee
ACA.E. Coleman
A.E. Coleman
AWA. Wang
A. Wang
AWA.D. Woolcock
A.D. Woolcock
SBS.A. Brown
S.A. Brown

1 November 2020 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
BLBianca N. Lourenço
Bianca N. Lourenço
ACAmanda E. Coleman
Amanda E. Coleman
SBScott A. Brown
Scott A. Brown
CSChad W. Schmiedt
Chad W. Schmiedt
MPMax C. Parkanzky
Max C. Parkanzky
KCKate Creevy
Kate Creevy
Background Information regarding efficacy of the angiotensin II receptor blocker, telmisartan, for treatment of proteinuria in dogs is limited. Objective To evaluate the antiproteinuric efficacy of telmisartan, as compared to enalapril, in dogs with chronic kidney disease and persistent, renal proteinuria. Animals Thirty‐nine client‐owned dogs with chronic kidney disease and urinary protein‐to‐creatinine ratio (UPC) > 0.5 (if azotemic) or ≥ 1.0 (if nonazotemic). Methods In this prospective, randomized, double‐masked clinical trial, dogs were block randomized, according to presence or absence of azotemia and systemic arterial hypertension, to receive telmisartan (1.0 mg/kg PO q24h), or enalapril (0.5 mg/kg PO q12h), and followed for 120 days. Up‐titration of study drug dosage on days 30 and 60, and addition of the other study drug at day 90, were performed if UPC > 0.5 was noted at these visits. Percentage change in UPC relative to baseline was calculated for all time points. Data are presented as median (range). Results Thirty‐nine (20 telmisartan‐treated, 19 enalapril‐treated) dogs were included. At day 30, percentage change in UPC was greater for telmisartan‐treated (−65% [−95% to 104%]) vs enalapril‐treated (−35% [−74% to 87%]) dogs (P = .002). Among dogs persistently proteinuric at earlier visits, telmisartan remained superior to enalapril at days 60 (P = .02) and 90 (P = .02). No difference in percentage change in UPC between study groups was observed at day 120, when combination therapy was allowed. Combination therapy resulted in relevant azotemia in 4/13 (31%) dogs. Conclusions and Clinical Importance Telmisartan might be a suitable first‐line therapy for dogs with renal proteinuria.